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INTRODUCTION
Medical practice and drug treatment should 
rely on solid scientific evidence, and it is general-
ly recognised that the standard basis for treatment 
guidelines is systematic reviews and meta-analy-
ses of all randomised controlled trials (19). Scientif-
ic evidence can only be valid if the studies included 
in the reviews and meta-analyses represent the com-
plete body of research and are not biased in such a 
way that conclusions misrepresent the effectiveness 
and safety of clinical interventions. However, as sys-
tematic reviews and meta-analyses are usually lim-
ited to publicly available data, several factors related 
to research dissemination and publication, can give 
rise to biased conclusions. These include selection of 
studies submitted or accepted for publication, inclu-
sion of undetected duplicate publications, and selec-
tive reporting (19).
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Publication bias refers to the distortion of data 
in scientific journals resulting from the fact that 
studies with significant and positive results are more 
likely to be published than studies with unfavor-
able - negative or insignificant results. Clinical de-
cision-making should be based on the totality of re-
search evidence and not on a sample biased by selec-
tive publication only of studies that show favorable 
results (28). 
Several actors (investigators, editors, and spon-
sors) affect whether and how scientific results reach 
the public domain (19). The role of the sponsor is es-
pecially influential for research dissemination - as 
it has access to all data on the investigated product 
and an obvious conflict of interest (5). In recent years 
sponsoring companies became very much involved 
in all aspects of research on their products. They of-
ten design the products, perform the analysis, write 
the paper, and decide whether, when and in what 
form to publish the results (16). 
Clinical studies are increasingly funded 
by pharmaceutical companies. Pharmaceutical 
industry, as the main sponsor of clinical trials, has 
gained unprecedented control over the evaluation 
of its own products and communication of research 
results. In some multicenter trials, authors may 
not even have access to their own data. Indeed, as 
drug industry’s influence over research has grown, 
so has the potential for bias in clinical trials. Drug 
companies now finance most clinical research on 
prescription drugs, and there is mounting evidence 
that they often skew the research and its reporting - 
to make their drugs look better and safer (16). Such 
manipulation of research outcomes communication 
might greatly jeopardize the scientific basis for 
clinical practice. 
This paper explores the aspects of clinical tri-
al performance that can be affected by sponsorship 
of pharmaceutical companies, particularly empha-
sizing on results dissemination  and publication. The 
aim is to describe the relationship between pharma-
ceutical industry sponsorship and bias in research 
publication. By revealing the scope of the problem 
and its essence - it attempts to sensitize the scientif-
ic, professional and publishing societies and provoke 
actions to prevent and control the problem. 
An electronic literature search was conducted 
in Medline, Web of Science, Cochrane Library and 
other database web sources for the last 25 years.
ESSENCE AND IMPACT OF PUB-
LICATION BIAS IN CLINICAL 
RESEARCH
Publication bias occurs when the publication of 
research results selectively depends on their nature 
and direction (28). The results of published studies 
will then be systematically different from those of 
unpublished studies. The fact that studies with pos-
itive or favourable results are more likely to be pub-
lished than those with negative or unfavourable re-
sults has been widely confirmed (6,18,19,30). Stud-
ies with positive or favourable results have been as-
sociated with other factors that could bias scientif-
ic evidence, such as: faster publication, publication 
in higher impact factor journals, a greater number 
of publications (including covert duplicate publica-
tions, more frequent citation, and more likely publi-
cation in English (18). 
A variation of publication bias is outcome-re-
porting bias, which is the selective reporting of some 
outcomes but not others, depending on their nature 
and direction. Outcomes are not only selectively re-
ported, but negative results are reported in a positive 
manner and conclusions are often not supported by 
results data (18). The existence of outcome-reporting 
bias in clinical research has also been confirmed by 
high-quality empirical studies (18,28).
Publication bias is known to be a major prob-
lem in the medical literature (7). It has the potential 
to reduce the quality and safety of health care out-
comes. As professional medical bodies construct evi-
dence-based guidelines on the basis of published tri-
al results, publication bias can compromise their rec-
ommendations. This contributes to excessive pre-
scription of expensive new drugs whose efficacy is 
overestimated and risks underestimated. Moreover, 
because the evidence is distorted, patients do not re-
ceive adequate treatment and information (24).
Publication bias has a considerable impact in 
studies funded by pharmaceutical companies. By 
concealing the unfavourable evidence about efficacy 
and safety, pharmaceutical companies deceive physi-
cians, their patients and, perhaps, shareholders (8,9). 
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Publication bias can prevent data of potential impor-
tance from reaching practicing health care providers. 
Such concealment represents a serious abuse of the 
trust freely offered to study investigators by research 
subjects. Unpublished studies, when they are unnec-
essarily repeated, also waste resources. 
As non-publication of research and its unfavor-
able results can distort scientific and medical knowl-
edge, it is largely impossible to reliably assess the ben-
efit and harm of medical drugs on the basis of pub-
lished trials. This will have repercussions for the re-
liability of meta-analyses, guidelines and patient in-
formation leaflets (2). A serious consequence may 
be undesired treatment errors. Indeed, recent con-
troversies in varied medical fields have highlighted 
the importance of having access to such unpublished 
data. Previously underappreciated unpublished side 
effect data have led to removal of certain agents from 
the pharmaceutical market (7). Marketing of other 
agents, for unproven treatment indications, also has 
led to controversies and even to malpractice lawsuits. 
For instance, a review of antidepressant random-
ized controlled trial (RCTs) in unipolar depression in 
the Food and Drug Administration (FDA) database 
found that almost all negative studies were unpub-
lished, leading to a false impression in the published 
literature that 93% of antidepressant RCTs had pos-
itive results; when unpublished studies were includ-
ed, 51% of all RCTs were positive and 49% were neg-
ative (7). Thus, unpublished studies raise questions 
of concerns regarding both underreported risks and 
underreported limitations in efficacy. 
With its negative impacts on clinical practice 
and ethical breaches - publication bias is generally 
accepted as serious scientific malpractice. 
INDUSTRY-INDUCED BIAS IN 
CLINICAL TRIALS 
Most clinical trials are sponsored by pharma-
ceutical companies, and commercial interests may 
determine the dissemination profile of a study. There 
has been an increasing number of studies suggesting 
that industry sponsored trials are biased in favor of 
the sponsor’s products (14).
Many systematic reviews have demonstrat-
ed that pharmaceutical industry sponsorship of 
drug and medical device studies is associated with 
findings that are favorable to the sponsor’s product 
(2,3,9,14,25,27). Industry sponsored drug and device 
studies more often have favorable efficacy results, 
harms results and overall conclusions, compared 
with non-industry sponsored drug and device stud-
ies. Bekelman and colleagues found that industry 
sponsorship was very strongly associated with pro-
industry conclusions (3). These findings were sup-
ported by Ridker and Torres, who carefully analyzed 
the randomized cardiovascular trials published in 
JAMA, The Lancet, and The New England Journal of 
Medicine. They found that the proportion of studies 
favoring newer treatments over the standard of care 
was significantly higher in trials funded by for-prof-
it organizations compared with trials funded by not-
for-profit organizations (21).  
Reviews of the impact of financial conflicts on 
biomedical research revealed that studies financed 
by industry always found outcomes favourable to the 
sponsoring company (14). It was demonstrated that 
industry-funded studies tend to emphasize favour-
able beneficial effects of the sponsor’s product, and to 
underestimate the adverse effects and patients’ risks. 
The nonpublication of negative outcomes in RCTs 
has been especially reported to occur in pharmaceu-
tical industry-funded studies, as opposed to studies 
funded by other sources (7).
It has been shown that more than half of the 
studies that are conducted as part of the drug approv-
al process will remain unpublished and these are tri-
als funded by for-profit companies failing to dem-
onstrate a positive outcome for the company’s prod-
uct. In addition, multiple publications of the same re-
sults, the selective use of data and the withholding 
of data relating to adverse drug reactions were wide-
ly demonstrated (14). Such findings apply across a 
wide range of disease states, drugs, and drug classes, 
and regardless of the type of research being assessed 
- pharmacoeconomic studies, clinical trials, or meta-
analyses of clinical trials (3). The evidence suggests 
that there is some kind of systematic bias to the out-
come of published research funded by the pharma-
ceutical industry (14).
Systematic investigations have been carried out 
aiming to spotlight the different stages and aspects 
of drug trials that are influenced by funding from 
the pharmaceutical industry. Various potential ways 
have been described in which pharmaceutical con-
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cerns exert influence on the outcome of a study and 
its communication, including the design of the study 
protocol, the conduct of the drug trial, the analysis of 
data, selective reporting of favorable results, and spin 
in reporting conclusions (23,26).
Numerous examples have been found of bias 
induced by sponsorship from pharmaceutical indus-
try in the areas of: research question, choice of dose 
and comparator agents, control over trial design and 
changes in protocols, early termination of clinical 
trials, reporting to regulatory authorities, reinter-
pretation of data, restrictions on publication rights, 
use of fake journals, journal supplements and sym-
posia, ghostwriting, publication and reporting of re-
sults and outcomes. On the other hand, the release of 
internal industry documents as a result of settlement 
agreements resulting from litigation against drug 
companies has revealed examples of industry manip-
ulation of the conduct and publication of studies (15). 
There has been evidence that pharmaceutical 
companies influenced study protocols in a way that 
was favorable to them. Execution of the study ac-
cording to plan and objective depiction of the results 
can also be influenced, e.g., by contractual stipula-
tions that grant the pharmaceutical company access 
to the trial data or give it the power to prevent the 
publication of results (24). 
Studies have empirically demonstrated that in-
dustry preferentially supports trial designs that fa-
vor positive results, such as: the use of placebo as the 
comparison therapy in controlled trials, active com-
parators in inferior doses, or inappropriate admin-
istration of the drugs (1,12). The frequent use of pla-
cebo controls in clinical trials has been often attrib-
uted to Food and Drug Administration regulations; 
however, the FDA does not require the use of place-
bo and is supportive of trials that incorporate active 
controls. Use of active controls does not eliminate the 
potential for bias; for instance, evidence from NSAID 
and fluconazole RCTs has revealed that inappropri-
ate administration and dosing disparities decrease 
the effectiveness of active controls (3). In the study by 
Rochon et al., in most cases in which the doses of the 
study and comparator drugs were not equivalent, the 
drug given at the higher dose was that of the support-
ing manufacturer (22). Higher doses may bias the re-
sults in favour of effectiveness of the manufacturer’s 
product. 
Pharmaceutical trials have been accused else-
where in the literature of using design modifications 
to ascertain lower adverse effects. Such methods may 
potentially include using lower doses of the interven-
tion and higher doses for the controls, monitoring 
for adverse effects using open-ended or nonspecific 
questions, and the choice of inappropriate compar-
ators. Industry sponsored studies may be biased in 
the coding of events and their data analysis (15) in a 
way that underestimate the undesired adverse effects 
of the investigated company’s product. Systematic re-
views also indicate that the funding source may im-
pact on the nature of the authors’ interpretation and 
conclusions regarding the safety profile (9). 
PUBLICATION BIAS IN INDUSTRY-
SPONSORED RESEARCH
Selective publication and outcome-reporting 
(publication bias) prove to be a major cause for bias in 
industry funded trials. Pharmaceutical industry and 
its sponsored investigators may selectively report fa-
vorable outcomes, fail to publish whole studies with 
unfavorable results, or publish studies with favorable 
results multiple times (15).
Many cases have been described in which the 
publication of studies with negative results has been 
suppressed by pharmaceutical companies. In the 
past few years, manufacturers have attempted to pre-
vent studies which are unfavourable to their prod-
ucts from being published in several high profile cas-
es (6,18,29). The withholding of negative and statis-
tically non-significant findings can result in publi-
cation bias, leading to a distorted perception of the 
therapeutic value of the drug concerned (24).
Further studies reveal evidence of other prob-
lems including incomplete trial registration, con-
straints on publishing rights, withheld  knowledge 
of adverse drug reactions, and the use of  ghostwrit-
ers who were supplied by the pharmaceutical compa-
nies. The presentation of results can be manipulat-
ed by ghostwriters and guest authors, where a well-
known opinion former is invited to be a guest author 
in order to underline the importance of the study 
results. 
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Consistent evidence also demonstrates that in-
dustry ties are associated with both publication de-
lays and data withholding. These restrictions, of-
ten contractual in nature, serve to compound bias in 
biomedical research. In addition, industry financing 
is also connected with multiple reporting of studies 
with positive outcomes, further compounding pub-
lication bias and potentially swaying review articles 
toward more positive results (18).
Massie and colleagues raised another possible 
source of publication bias. They showed that research 
funded by the industry appears more often in sym-
posiums (17). Studies in symposiums are known to 
lack peer review and to favour the sponsor’s product, 
therefore the absence of peer review may result in an 
overly favourable interpretation of the results of a tri-
al. Rochon and colleagues noted that claims of su-
periority for the sponsor’s product claimed in sym-
posia presentations, were often not supported by the 
data (15).
CONFLICT OF INTEREST IN IN-
DUSTRY-SPONSORED RESEARCH 
Pharmaceutical companies fund the vast ma-
jority of the clinical research that is undertaken on 
medications but face a conflict of interest between 
producing good science and results that will enhance 
the sales of their products (13). This entails an ob-
vious contradiction, as on one side, drugs as a tech-
nology are used to cure diseases and relieve symp-
toms; on the other, they are produced mainly by cor-
porations with a firm footing in the economic mar-
ket and are subject to the market’s laws and driven by 
the pursuit of profit. 
The pharmaceutical and medical device in-
dustries have strong interests in scientific publica-
tions that present their products positively, as pub-
lications are the basis of regulatory, purchasing, and 
medical decisions (4). Results and conclusions that 
are unfavorable to the sponsor (i.e. studies that find 
an expensive drug similarly or less effective or more 
harmful than drugs used to treat the same condition) 
can pose considerable financial risks to the compa-
nies. Therefore, drug companies may be particularly 
unwilling to publish sponsored trials with unfavour-
able results (15). Companies may also try to prevent 
the publication of studies conducted by others when 
the findings will undermine their commercial inter-
ests. These interests can influence the design, con-
duct and publication of studies in ways that make the 
sponsor’s product appear better than the comparator 
product (16). The pharmaceutical industry has less 
to do with health than with business, investments, 
stock prices, and financial gain. This contradiction 
produces devastating effects that have become pro-
gressively more visible to health professionals and re-
searchers, triggering vigorous challenges (16). 
PREVENTION OF PUBLICATION 
BIAS IN INDUSTRY-SPONSORED 
RESEARCH
An effective approach for prevention of publi-
cation bias induced by industry should consider the 
financial conflicts of interest in clinical research. 
The safety of patients must remain the paramount 
concern, bias in the research process must be mini-
mized, and appropriate incentives for research inno-
vation must be preserved. For the purpose, bias pre-
ventive measures must take into account the indus-
trialization of clinical research and the conflict of in-
terests involved in industry-sponsored trials.
Both medical associations and research journal 
editors have become concerned with conflicts of in-
terest in the conduct of clinical research. Editors and 
academics have criticised companies for selective re-
porting of clinical trials, duplicate publication and 
various other forms of manipulation of research out-
come communication. Guideline documents have 
been developed to address these issues and increase 
the credibility of studies paid for by drug companies. 
Leading medical journals established more rig-
orous criteria for the acceptance of research spon-
sored by industry (14). The ICMJE Uniform require-
ments revision (11) calls for full disclosure of the 
sponsor‘s role in research, as well as assurance that 
the investigators are independent of the sponsor, are 
fully accountable for the design and conduct of the 
trial, have independent access to all trial data and 
control all editorial and publication decisions. The 
CONSORT (Consolidated standards of reporting 
trials) Statement was endorsed by prominent medi-
cal journals and leading editorial organizations (14). 
Pharmaceutical organizations implemented  recom-
mendations that are intended to ensure comprehen-
sive publication of research findings, whether posi-
tive or negative. In 2002, the Pharmaceutical Re-
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search and Manufacturers Association (PhRMA) 
published its “Principles on the Conduct of Clinical 
Trials and Communication of Clinical Trial Results” 
(20). Similarly, Good Publication Practice (GPP) for 
pharmaceutical companies was also set up aimed at 
improving the behaviour of drug companies while 
reporting drug trials (10). 
Besides these initiatives on the part of medical 
organizations, leading journals and the pharmaceu-
tical industry - negative results of industry sponsored 
research are still not published in timely fashion and 
control mechanisms fail. The findings of recent stud-
ies suggest that investigators and sponsors undertak-
ing human participant research do not adhere to the 
endorsed standards of accountability, access to data 
and control of publication (10). 
Mandatory prospective registration of clinical 
trials and full study results after study completion, 
as well as public access to study data via results data-
bases need to be introduced on a worldwide level (18). 
This would help fulfil ethical obligations towards pa-
tients by enabling proactive publication and indepen-
dent reviews of clinical trial data, and ensure a basis 
for fully informed decision making in the health care 
system. Otherwise, clinical decision making based 
on the „best evidence“ will remain an illusion.
CONCLUSIONS 
An increasing number of clinical trials are 
funded by the pharmaceutical industry, and the in-
dustry has strong interests in scientific publications 
that present their products positively. Strong and 
consistent evidence shows that industry-sponsored 
research tends to draw pro-industry biased conclu-
sions. Publication bias is proved to be a major cause 
for bias in industry funded trials. Published drug tri-
als that are financed by pharmaceutical companies 
may often present a distorted picture, which seriously 
impacts on validity of scientific evidence – a basis for 
clinical decisions. Therefore rigorous coherent mea-
sures must be taken by all – scientific and medical 
organizations, ethical committees, regulatory bod-
ies, journal editors and the industry itself - to ensure 
that commercial pharmaceutical interests do not un-
dermine the knowledge of scientifically correct study 
planning, study execution, and publication.
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